MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
3.130
-0.010
-0.32%
After Hours: 3.130 0 0.01% 16:33 05/11 EDT
OPEN
3.145
PREV CLOSE
3.140
HIGH
3.150
LOW
3.120
VOLUME
19.78M
TURNOVER
--
52 WEEK HIGH
4.175
52 WEEK LOW
0.6925
MARKET CAP
805.76M
P/E (TTM)
-28.6893
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ESPR last week (0504-0508)?
Weekly Report · 14h ago
Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk
TipRanks · 1d ago
EXE, IP, ESPR, CMPS, TNXP Trending With Analysts
TipRanks · 2d ago
Esperion Q1 net loss narrows to $25.2 million; product sales rise to $43.4 million
PUBT · 3d ago
Esperion Therapeutics Q1 2026 Earnings Preview
Seeking Alpha · 5d ago
U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, Onsemi
Reuters · 6d ago
BRIEF-BioPharma Credit Says Co's Allocation Of Financing Of Esperion Deal Between $78 Million And $120 Million
Reuters · 6d ago
BIOPHARMA CREDIT PLC - CO'S ALLOCATION OF FINANCING OF ESPERION DEAL BETWEEN $78 MLN AND $120 MLN
Reuters · 6d ago
More
About ESPR
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.